CLAIMS:

1. A compound of Formula (0):



(Formula (0))

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is a 6- to 10-membered, monocyclic or bicyclic heterocycloalkyl or heterocycloalkenyl group comprising at least one ring atom which is N, and wherein R^1 is optionally substituted by one or more groups independently selected from =O, CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)OH, $C(O)NH_2$, $C(O)ONH_2$, C(O)R*, C(O)OR*, OC(O)R*, C(O)NHR*, $CH_2C(O)NHR*$, $C(O)NR*_2$, $CH_2C(O)NR*_2$, C(O)ONHR*, $CH_2C(O)ONHR*$, $C(O)ONR*_2$ and $CH_2C(O)ONR*_2$; or wherein R^1 is $-L^3-R^{1'}$, wherein $R^{1'}$ is a 5-membered, monocyclic heterocycloalkyl or heterocycloalkenyl group comprising at least one ring atom which is N, and wherein $R^{1'}$ is optionally substituted by one or more groups independently selected from =O, CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)OH, $C(O)NH_2$, $C(O)ONH_2$, C(O)R*, C(O)OR*, C(O)NHR*, $C(O)NR*_2$, C(O)ONHR*, and $C(O)ONR*_2$;

R^2 is a 5- to 9-membered, monocyclic or bicyclic heterocycloalkyl or heterocycloalkenyl group comprising at least one ring atom which is N or O; a 5- or 6-membered monocyclic heteroaryl group comprising at least one ring atom which is N; a fused, 8- to 10-membered bicyclic group wherein one or both rings are aromatic, and wherein at least one ring comprises at least one ring atom which is N; or a fused, 11- to 14-membered tricyclic group wherein at least one ring is aromatic, and wherein at least one ring comprises at least one ring atom which is N;

and wherein R^2 may be substituted by one or more groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, =O, $(C_2$-$C_3)$alkenyl, and $(C_2$-$C_3)$alkynyl;

R^3 is a phenyl or naphthalenyl group which is substituted by OH and optionally by one or more additional groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, $(C_2$-$C_3)$alkenyl, or $(C_2$-$C_3)$alkynyl; or R^3 is a fused, 8-to-10-membered bicyclic group

comprising a saturated carbocyclic ring fused to a heterocyclic ring, wherein the carbocyclic ring, the heterocyclic ring, or both, may optionally be substituted by one or more groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, NHC(O)R*, (C_2-C_3)alkenyl, or (C_2-C_3)alkynyl; or R^3 is a fused, 8- to 10-membered bicyclic group comprising a saturated carbocyclic ring fused to an aryl ring, wherein the carbocyclic ring, the aryl ring, or both, may be optionally substituted by one or more groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, NHC(O)R*, (C_2-C_3)alkenyl, or (C_2-C_3)alkynyl; or R^3 is a fused, 8- to 10-membered bicyclic group comprising a saturated heterocyclic ring fused to an aryl or heteroaryl ring, wherein the carbocyclic ring, the aryl or heteroaryl ring, or both, may be optionally substituted by one or more groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, NHC(O)R*, (C_2-C_3)alkenyl, or (C_2-C_3)alkynyl;

L^1 is a bond or is -O-, -(C_1-C_3)alkyl-, *-O-(C_1-C_3)alkyl-**, *-(C_1-C_3)alkyl-O-**, *-C(O)NR'-**, or *-NR'C(O)-**, wherein R' is H, OH, CN, Cl, F, or (C_1-C_3)alkyl, and * denotes a point of attachment to the triazole moiety of the compound of Formula (0) and ** denotes a point of attachment to R^2;

L^2 is -(C_1-C_3)alkyl-, C_5-heteroaryl optionally substituted with one or more R'', *-O-(C_1-C_3)alkyl-**, *-(C_1-C_3)alkyl-O-**, -(C_2-C_3)alkenyl-, -(C_2-C_3)alkynyl-, *-(C_1-C_3)alkyl-NR''-**, *-NR''(C_1-C_3)alkyl-**, *-C(O)NR''-**, *-NR''C(O)-**, *-NR''-(C_1-C_3)alkyl-**, or *-(C_1-C_3)alkyl-NR''-**, wherein R'' is H, OH, CN, Cl, F, or (C_1-C_3)alkyl, and wherein * denotes a point of attachment to R^3 and ** denotes a point of attachment to the triazole moiety of the compound of Formula (0);

L^3 is a bond or is -(C_1-C_3)alkyl-, -O-, -NH- or -N(C_1-C_3) alkyl;

and

wherein in R^1, R^2, and R^3, each R* is independently selected from (C_1-C_4)alkyl, (C_2-C_3)alkenyl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkenyl, and 5- or 6-membered monocyclic heteroaryl, wherein said (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkenyl or 5- or 6-membered monocyclic heteroaryl may itself be substituted by one or more groups independently selected from F, Cl, CN, OH, NH_2, NH((C_1-C_3)alkyl), (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_2-C_3)alkynyl, or O(C_1-C_3) alkyl.

2. The compound or pharmaceutically acceptable salt of claim 1, wherein the compound is a compound of Formula (I):



(Formula (I))

wherein in Formula (I):

R^1 is a 6- to 10-membered bridged bicyclic heterocycloalkyl or heterocycloalkenyl group comprising at least one ring atom which is N, and wherein R^1 is optionally substituted by one or more groups independently selected from =O, CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)OH, $C(O)NH_2$, $C(O)ONH_2$, C(O)R*, C(O)OR*, C(O)NHR*, $C(O)NR*_2$, C(O)ONHR*, and $C(O)ONR*_2$;

R^2 is a 5- to 8-membered, monocyclic or bicyclic heterocycloalkyl or heterocycloalkenyl group comprising at least one ring atom which is N or O; a 5- or 6-membered monocyclic heteroaryl group comprising at least one ring atom which is N; or a fused, 8- to 10-membered bicyclic group wherein one or both rings are aromatic, and wherein at least one ring comprises at least one ring atom which is N;

and wherein R^2 may be substituted by one or more groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, =O, $(C_2$-$C_3)$alkenyl, and $(C_2$-$C_3)$alkynyl;

R^3 is a phenyl or naphthalenyl group which is substituted by OH and optionally by one or more additional groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, $(C_2$-$C_3)$alkenyl, or $(C_2$-$C_3)$alkynyl; or R^3 is a fused, 8-to-10-membered bicyclic group comprising a saturated carbocyclic ring fused to a heterocyclic ring, wherein the carbocyclic ring, the heterocyclic ring, or both, may optionally be substituted by one or more groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, $(C_2$-$C_3)$alkenyl, or $(C_2$-$C_3)$alkynyl;

L^1 is -O-, -(C_1-C_3)alkyl-, *-O-(C_1-C_3)alkyl-**, *-(C_1-C_3)alkyl-O-**, *-C(O)NR'-**, or *-NR'C(O)-**, wherein R' is H, OH, CN, Cl, F, or (C_1-C_3)alkyl, and * denotes a point of attachment to the triazole moiety of the compound of Formula (I) and ** denotes a point of attachment to R^2;

L^2 is -(C_1-C_3)alkyl-, C_5-heteroaryl optionally substituted with one or more R'', *-O-(C_1-C_3)alkyl-**, *-(C_1-C_3)alkyl-O-**, -(C_2-C_3)alkenyl-, -(C_2-C_3)alkynyl-, *-(C_1-C_3)alkyl-NR''-**, *-NR''(C_1-C_3)alkyl-**, *-C(O)NR''-**, *-NR''C(O)-**, *-NR''-(C_1-C_3)alkyl-**, or *-(C_1-C_3)alkyl-NR''-**, wherein R'' is H, OH, CN, Cl, F, or (C_1-C_3)alkyl, and wherein * denotes a point of attachment to R^3 and ** denotes a point of attachment to the triazole moiety of the compound of Formula (I);

and

wherein in R^1, R^2, and R^3, each R* is independently selected from (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_3-C_6)cycloalkyl, and (C_3-C_6)cycloalkenyl, wherein said (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_3-C_6)cycloalkyl, or (C_3-C_6)cycloalkenyl may itself be substituted by one or more groups independently selected from F, Cl, CN, OH, NH_2, NH((C_1-C_3)alkyl), (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_2-C_3)alkynyl, or O(C_1-C_3) alkyl.

3. The compound or pharmaceutically acceptable salt thereof of claim 1 or claim 2, wherein R^1 is , , , , , ,



,


,


,


,


or


.

4. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 3, wherein R^3 is selected from



wherein m is 1 or 2 and n is 0, 1, or 2; and each R^c and R^d is independently selected from F, Cl, CN, OH, (C_1-C_3)alkyl, (C_2-C_3)alkenyl, and (C_2-C_3)alkynyl, provided that at least one R^c is OH;



, wherein s is 1, 2, or 3, and wherein when s is 1 R^g is OH, and when s is 2 or 3, at least one R^g is OH and each remaining R^g is independently F, Cl, CN, OH, (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_2-C_3)alkynyl, or (C_3-C_6)cycloalkyl, wherein said (C_3-C_6)cycloalkyl may itself be

substituted by one or more groups independently selected from F, Cl, CN, OH, (C_1-C_3)alkyl, (C_2-C_3)alkenyl, or (C_2-C_3)alkynyl; and



, wherein Y^{10} is S, O, or NR''' wherein R''' is H, OH, CN, Cl, F, or (C_1-C_3)alkyl; t is 0, 1, 2, or 3 and u is 0, 1, or 2, with the proviso that when t is zero, u is nonzero, and that when u is zero, t is nonzero; and each R^h and R^i is independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, NR^*_2, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR^*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR^*_2$, (C_2-C_3)alkenyl, and (C_2-C_3)alkynyl, wherein R* is as defined in claim 1 or claim 2;

preferably wherein R^3 is selected from:



,



, and



,

optionally wherein R^3 is selected from:



,



,



,



,


,


,


, and


.

5. The compound or pharmaceutically acceptable salt thereof of any of claims 1 to 4, wherein L^2 is selected from:

-CH_2CH_2-, -C≡C-, *-CH_2O-**, *-OCH_2-**, *-C(O)-NH-**, *-CH_2NH-**, *-$N(CH_3)C(O)$-**, *-NHC(O)-**, and 

,

and wherein * and ** are as defined in claim 1 or claim 2.

6. The compound or pharmaceutically acceptable salt thereof of any of claims 1 to 5, wherein R^2 is selected from:



, wherein q and r are each independently 0, 1, or 2, and each instance of R^a and R^b is independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, NR^*_2, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR^*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR^*_2$, =O, $(C_2$-$C_3)$alkenyl, and $(C_2$-$C_3)$alkynyl, wherein R* is as defined in claim 1 or claim 2;



, wherein X^8, X^9, X^{10}, and X^{11} are each independently selected from $C(R^k)_2$, C=O, $N(R^k)$, O, or S, provided that at least one of X^8, X^9, X^{10}, and X^{11} is $N(R^k)$;



, wherein X^{12}, X^{13}, and X^{14} are each independently selected from $C(R^k)_2$, C=O, $N(R^k)$, O, or S and X^{15} and X^{16} are each independently selected from C and N, provided that at least one of X^{12}, X^{13}, and X^{14} is $N(R^k)$ and/or at least one of X^{15} and X^{16} is N;



, wherein X^{17}, X^{18}, X^{19}, X^{20}, and X^{21} are each independently selected from $C(R^k)_2$, C=O, $N(R^k)$, O, or S, provided that at least one of X^{17}, X^{18}, X^{19}, X^{20}, and X^{21} is $N(R^k)$, O, or S;



, wherein Y^1, Y^2, Y^3, and Y^4 are each independently N, O, S, NR^k, or CR^k, provided that at least one of Y^1, Y^2, Y^3, and Y^4 is N or NR^k;



, wherein Y^5, Y^6, and Y^7 are each independently N, O, S, NR^k, or CR^k, and Y^8 and Y^9 are each independently N or C, provided that at least one of Y^5, Y^6, and Y^7 is N or NR^k and/or at least one of Y^8 and Y^9 is N;

and 

, wherein Z^1, Z^2, Z^3, Z^4, and Z^5 are each independently N, O, S, or CR^k, provided that at least one of Z^1, Z^2, Z^3, Z^4, and Z^5 is N;

wherein each R^k is independently selected from H, CN, Cl, F, R*, OH, OR*, NH_2, NHR*, NR^*_2, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR^*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR^*_2$, $(C_2\text{-}C_3)$alkenyl, and $(C_2\text{-}C_3)$alkynyl, and wherein R* is as defined in claim 1 or claim 2;

preferably wherein R^2 is selected from:



(e.g. wherein 

is 

), 

(e.g. wherein 

is 

, 

, 

, 

, 

, or 

), 

,



7. The compound or pharmaceutically acceptable salt of any of claims 1 to 6, wherein L^1 is -O-, *-OCH(CH_3)-**, or *-O-CH_2-**.

8. The compound or pharmaceutically acceptable salt thereof of claim 1 or claim 2, wherein the compound is a compound of Formula (III), Formula (IV), Formula (VI), Formula (VI.I), Formula (XXII), Formula (XXII.I), Formula (XXIII.I), or Formula (XXIV.I):



(Formula (III))



(Formula (IV))



(Formula (VI))



(Formula (VI.I))



(Formula (XXII));



(Formula (XXII.I))



(Formula (XXIII.I))



(Formula (XXIV.I))

wherein

in each of Formula (III), Formula (IV), Formula (XXII), L^1 is as defined in claim 1, claim 2, or claim 7; L^2 is as defined in claim 1, claim 2, or claim 5; R*' is selected from H, CN, Cl, F, R*, OR*, $NR*_2$, CHO, C(O)R*, C(O)OR*, $C(O)NR*_2$, and $C(O)ONR*_2$, wherein R* is as defined in claim 1 or claim 2; and R^2 is as defined in claim 6;

in Formula (III), R^c, R^d, n and m are as defined in claim 4;

in Formula (IV), R^g and s are as defined in claim 4; and

in Formula (XXII), R^h, R^i, t, u, and Y^{10} are as defined in claim 4; and

in Formula (XXII.I), L^1 is as defined in claim 1, claim 2, or claim 7; L^2 is as defined in claim 1, claim 2, or claim 5; R^2 is as defined in claim 6; R^h, R^i, t, u, and Y^{10} are as defined in claim 4; X is selected from NH, N(C_{1-3})alkyl, O, or CH_2; v is an integer from 0 to 4; and each R*'' is independently selected from H, CN, Cl, F, R*, OH, OR*, $NR*_2$, CHO, C(O)R*, C(O)OR*, $C(O)NR*_2$, and $C(O)ONR*_2$, wherein R* is as defined in claim 1 or claim 2;

in Formula (VI), L^1 is as defined in claim 1, claim 2, or claim 7; L^2 is as defined in claim 1, claim 2, or claim 5; R*' is selected from H, CN, Cl, F, R*, OR*, $NR*_2$, CHO, C(O)R*, C(O)OR*, $C(O)NR*_2$, and $C(O)ONR*_2$, wherein R* is as defined in claim 1 or claim 2; and R^3 is as defined in claim 4;

in Formula (VI.I), L^1 is as defined in claim 1, claim 2, or claim 7; L^2 is as defined in claim 1, claim 2, or claim 5; X is selected from NH, N(C_{1-3})alkyl, O, or CH_2; v is an integer from 0 to 4; each R*'' is independently selected from H, CN, Cl, F, R*, OH, OR*, $NR*_2$, CHO, C(O)R*, C(O)OR*, $C(O)NR*_2$, and $C(O)ONR*_2$, wherein R* is as defined in claim 1 or claim 2; and R^3 is as defined in claim 4; and

in each of Formula (XXIII.I) and Formula (XXIV.I):
L^1 is as defined in claim 1, claim 2, or claim 7; L^2 is as defined in claim 1, claim 2, or claim 5; R^h, R^i, t, and u are as defined in claim 4; X is selected from NH, N(C_{1-3})alkyl, O, or CH_2; v is an integer from 0 to 4; each R*'' is independently selected from H, CN, Cl, F, R*, OH, OR*, $NR*_2$, CHO, C(O)R*, C(O)OR*, $C(O)NR*_2$, and $C(O)ONR*_2$, wherein R* is as defined in claim 1 or claim 2; and R^2 is as defined in claim 6.

9. A compound of Formula (XXII) or Formula (XXII.I), Formula (XXIII.I) or Formula (XXIV.I) as defined in claim 8, or a pharmaceutically acceptable salt thereof, wherein R^2 is a 5- to 9-membered, monocyclic or bicyclic heterocycloalkyl or heterocycloalkenyl group comprising at least one ring atom which is N or O; a 5- or 6-membered monocyclic heteroaryl group comprising at least one ring atom which is N; a fused, 8- to 10-membered bicyclic group wherein one or both rings are aromatic, and wherein at least one ring comprises at least one ring atom which is N; and wherein R^2 may be substituted by one or more groups independently selected from CN, Cl, F, R*, OH, OR*, NH_2, NHR*, $NR*_2$, CHO, C(O)R*, C(O)OH, C(O)OR*, $C(O)NH_2$, C(O)NHR*, $C(O)NR*_2$, $C(O)ONH_2$, C(O)ONHR*, $C(O)ONR*_2$, =O, (C_2-C_3)alkenyl, and (C_2-C_3)alkynyl; and

wherein each R* is independently selected from (C_1-C_4)alkyl (*e.g.* C_1-C_3)alkyl), (C_2-C_3)alkenyl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkenyl, and 5- or 6-membered monocyclic heteroaryl, wherein said (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkenyl or 5- or 6-membered monocyclic heteroaryl may itself be substituted by one or more groups independently selected from F, Cl, CN, OH, NH_2, NH((C_1-C_3)alkyl), (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_2-C_3)alkynyl, or O(C_1-C_3) alkyl.

10. A compound or pharmaceutically acceptable salt thereof of claim 9, wherein R^2 is , wherein X^8, X^9, X^{10}, and X^{11} are as defined in claim 6, optionally wherein R^2 is  as defined in claim 6, e.g. wherein R^2 is ,  or .

11. The compound or pharmaceutically acceptable salt of claim 1 or claim 2, wherein the compound is a compound of Formula (VIII), Formula (X), Formula (XXV), Formula (XXVII) or Formula (XXVIII):



Formula (VIII)



Formula (X)



(Formula (XXV),



(Formula (XXVII))



(Formula (XXVIII))

wherein

in each of Formula (VIII), Formula (X), and Formula (XXV), L^1 is as defined in claim 1, claim 2, or claim 7; L^2 is as defined in claim 1, claim 2, or claim 5; R^1 is as defined in claim 1 or claim 2, or R^1 is , , , or ; and R^a, R^b, q, and r are as defined in claim 6;

in Formula (VIII), R^c, R^d, n, and m are as defined in claim 4;

in Formula (X), R^g and s are as defined in claim 4; and

in Formula (XXV), R^h, R^i, t, u, and Y^{10} are as defined in claim 4;

in Formula (XXVII), L^1 is as defined in claim 1, claim 2, or claim 7; L^2 is as defined in claim 1, claim 2, or claim 5; R^k is as defined in claim 6; X is selected from NH, $N(C_{1-3})$alkyl, O, or CH_2; v is an integer from 0 to 4; each R*'' is independently selected from H, CN, Cl, F, R*, OH, OR*, NR^*_2, CHO, C(O)R*, C(O)OR*, $C(O)NR^*_2$, and $C(O)ONR^*_2$, wherein R* is as defined in claim 1 or claim 2; and R^3 is as defined in claim 4; and

in Formula (XXVIII), L^1 is as defined in claim 1, claim 2, or claim 7; L^2 is as defined in claim 1, claim 2, or claim 5; R^k is as defined in claim 6; X is selected from NH, $N(C_{1-3})$alkyl, O, or CH_2; v

is an integer from 0 to 4; each R*'' is independently selected from H, CN, Cl, F, R*, OH, OR*, $NR*_2$, CHO, C(O)R*, C(O)OR*, $C(O)NR*_2$, and $C(O)ONR*_2$, wherein R* is as defined in claim 1 or claim 2; and wherein R^h, R^i, t and u are as defined in claim 4.

12. A pharmaceutical composition comprising the compound of any one of claims 1-11 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient or carrier.

13. A compound or pharmaceutically acceptable salt according to any one of claims 1-11, or a pharmaceutical composition according to claim 12, for use in therapy.

14. A compound or pharmaceutically acceptable salt according to any one of claims 1-11, or a pharmaceutical composition according to claim 12, for use in the treatment or prevention of cancer, preferably wherein the cancer is a KRAS G12D-associated cancer, optionally wherein the cancer is selected from colorectal cancer, lung cancer, and pancreatic cancer.

15. Use of a compound or pharmaceutically acceptable salt according to any one of claims 1-11, or a pharmaceutical composition according to claim 12, in the manufacture of a medicament for treating or preventing a disease or disorder mediated by KRAS G12D, or a disease or disorder in which KRAS G12D is implicated, or a disease or disorder associated with KRAS G12D, in a subject in need thereof, preferably wherein the disease or disorder associated with KRAS G12D is a KRAS G12D-associated cancer, optionally wherein the cancer is selected from colorectal cancer, lung cancer, and pancreatic cancer.

16. Use of a compound or pharmaceutically acceptable salt according to any one of claims 1-11, or a pharmaceutical composition according to claim 12, in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof, preferably wherein the cancer is a KRAS G12D-associated cancer, optionally wherein the cancer is selected from colorectal cancer, lung cancer, and pancreatic cancer.

17. Use of a compound or pharmaceutically acceptable salt according to any one of claims 1-11, or a pharmaceutical composition according to claim 12, in the manufacture of a medicament for inhibiting KRAS G12D activity.